Cooley advised Reka on the fundraising. Reka announced its funding of $58 million dollars led by DST Global Partners and founding investor Radical Ventures along with participation from...
You must be a Standard 1 Year member to access this content.
Cooley advises ThoughtSpot on the deal. ThoughtSpot announced it has signed a definitive agreement to acquire Mode Analytics in a cash and equity deal valued at $200...
You must be a Standard 1 Year member to access this content.
Cooley is serving as legal counsel to Tourmaline in connection with the private placement and the merger, while Goodwin Procter is serving as legal counsel to...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Cooley represent MindMed in connection with the proxy contest. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) has announced its successful proxy...
You must be a Standard 1 Year member to access this content.
Cooley advised Thirty Madison on the deal. Thirty Madison announced that it will ensure continued care for over a hundred thousand patients after strategically acquiring assets,...
You must be a Standard 1 Year member to access this content.
Cooley advised Synthesia on the fundraising. Synthesia raised $90 million in Series C funding to continue its work to make video production simple and intuitive without...
You must be a Standard 1 Year member to access this content.
Cooley advised Cholesgen on the deal. Cholesgen (Shanghai) Co.Ltd. announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with...
You must be a Standard 1 Year member to access this content.
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
You must be a Standard 1 Year member to access this content.
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
You must be a Standard 1 Year member to access this content.
Cooley advised Ionis Pharmaceuticals on the offering. Ionis Pharmaceuticals, a biotechnology company, announced the offering of $575 million aggregate principal amount of convertible senior notes, including the exercise...
You must be a Standard 1 Year member to access this content.
Cooley advised Snyk on the deal. Snyk announced it agreed to acquire Enso Security, pioneers of the industry’s first Application Security Posture Management (ASPM) solution. The...
You must be a Standard 1 Year member to access this content.
Cooley advised 2045 on the financing. 2045, an exclusive membership network for influential professionals of color, announced its launch and $4.2 million pre-seed financing. Benchstrength led the...
You must be a Standard 1 Year member to access this content.
